301089.SHE Xinxiang Tuoxin Pharmaceutical Co.Ltd.
- Market cap
- CNY 2.55B
- P/E
- -
- P/B
- 1.76x
- ROE
- -3.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301089.SHE undervalued?
Graham numberThe Graham number of Xinxiang Tuoxin Pharmaceutical Co.Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xinxiang Tuoxin Pharmaceutical Co.Ltd. fundamental analysis
No fundamental analysis for Xinxiang Tuoxin Pharmaceutical Co.Ltd. yet.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, an…
Full company profileXinxiang Tuoxin Pharmaceutical Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 386M | 528M | 502M | 785M | 836M | 422M | 378M | 430M |
| Gross Profit | 159M | 225M | 191M | 472M | 484M | 126M | 99.8M | 81.9M |
| Operating Income | 82.5M | 151M | 90.5M | 325M | 326M | -13.9M | -47.6M | -51.9M |
| EBITDA | 159M | 195M | 118M | 369M | 363M | 20.0M | -5.96M | -57.7M |
| Net Income | 61.3M | 113M | 65.7M | 287M | 243M | -19.9M | -69.7M | -54.6M |
| EPS | 0.65 | 1.19 | 0.52 | 2.27 | 1.92 | -0.16 | -0.55 | -0.43 |
| Balance Sheet | ||||||||
| Total Assets | 740M | 946M | 1.39B | 1.84B | 1.84B | 1.76B | 1.67B | 1.62B |
| Total Liabilities | 357M | 456M | 296M | 467M | 236M | 206M | 181M | 170M |
| Shareholders' Equity | 383M | 491M | 1.10B | 1.38B | 1.60B | 1.55B | 1.48B | 1.45B |
| Cash & Short-term Investments | 104M | 158M | 284M | 307M | 149M | 69.2M | 140M | 81.6M |
| Cash Flow | ||||||||
| Operating Cash Flow | 86.4M | 120M | 58.2M | 269M | 27.0M | 103M | -26.2M | - |
| Capital Expenditure | 76.2M | 74.1M | 113M | 148M | 185M | 83.9M | 44.5M | 60.7M |
| Free Cash Flow | 10.2M | 45.9M | -54.5M | 121M | -158M | 18.8M | -70.6M | -68.7M |
| Ratios | ||||||||
| ROE | 16.0% | 23.0% | 6.0% | 20.8% | 15.2% | -1.3% | -4.7% | -3.8% |
| ROA | 8.3% | 11.9% | 4.7% | 15.5% | 13.2% | -1.1% | -4.2% | -3.4% |
| Net Profit Margin | 15.9% | 21.4% | 13.1% | 36.5% | 29.1% | -4.7% | -18.4% | -12.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 23, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 31.6M | 0.25 | - |
| 2023 | CNY 50.7M | 0.40 | 20.8% |
| 2022 | CNY 15.0M | 0.12 | 5.2% |
| 2021 | CNY 7.92M | 0.06 | 12.1% |
| 2020 | CNY 9.60M | 0.10 | 8.5% |
| 2019 | CNY 14.0M | 0.15 | 22.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Xinxiang Tuoxin Pharmaceutical Co.Ltd.
- Insiders 54.48%
- Institutions 0.10%
- Public & others 45.41%
- Shares outstanding 127M
- Free float 59.3M
Xinxiang Tuoxin Pharmaceutical Co.Ltd. company profile
- Company name
- Xinxiang Tuoxin Pharmaceutical Co.Ltd.
- Ticker
- 301089.SHE
- ISIN
- CNE100004YC3
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,543
- Fiscal year end
- December
- Address
- No. 515, Kelong Avenue, High-tech Zone, Xinxiang, China, 453000
- Phone
- 86 37 3635 1898
- Website
- tuoxinpharm.com
About Xinxiang Tuoxin Pharmaceutical Co.Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is based in Xinxiang, China.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. management
7- Mr. Shaohua YangGM & Non-Independent Director · born 1994
- Ms. Huijuan JiaoChief Financial Officer · born 1966
- Ms. Yuying CaiVP & Director · born 1963
- Ms. Yuhua YangDeputy GM & Board Secretary · born 1990
- Mr. Xiuqiang WangDeputy General Manager · born 1970
- Mr. Tao LiDeputy General Manager · born 1981
- Zhen Wei YuAccounting Supervisor